Arcturus Therapeutics (ARCT) Stock Statistics & Valuation Metrics

Arcturus Therapeutics has a market cap or net worth of $223.41M. The enterprise value is $22.45.

Arcturus Therapeutics has 28,423,069 shares outstanding. The number of shares has decreased by -2.65% in one year.

Arcturus Therapeutics’s return on equity (ROE) is -0.31 and return on invested capital (ROIC) is -31.36%.

The current PE Ratio of Arcturus Therapeutics is ―. Arcturus Therapeutics’s PEG ratio is 0.13.

In the last 12 months, Arcturus Therapeutics had revenue of 67.22M and earned -65.78M in profits. Earnings per share was -2.40.

In the last 12 months, operating cash flow was -72.73M and capital expenditures -318.66K, giving a free cash flow of -73.05M billion.

Arcturus Therapeutics pays an annual dividend of $0.06, resulting in a dividend yield of ―

Arcturus Therapeutics upcoming earnings date is Nov 11, 2026, After Close (Confirmed).

Arcturus Therapeutics as a current ratio of 6.64, with Debt / Equity ratio of 13.35%

In the past 12 months, Arcturus Therapeutics has paid 0.00 in taxes.

Arcturus Therapeutics EV to EBITDA ratio is 0.61, with an EV/FCF ratio of 0.51.

Arcturus Therapeutics has $191.48M in cash and marketable securities with $22.93M in debt, giving a net cash position of $168.55M billion.

Gross margin is 83.19%, with operating margin of -111.51%, and net profit margin of -97.86%.

The average price target for Arcturus Therapeutics is $19.80, which is 11.43% higher than the current price. The consensus rating is Moderate Buy